A Phase 2 interventional study of eltrombopag and Cyclosporine in Severe Aplastic Anemia, sponsored by Novartis Pharmaceuticals. Completed at 20 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 5th largest by enrollment, is one of 2 that started in 2017, is one of 11 in phase 2, and was the 9th registered.
372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.
Browse Anemia, Aplastic studies →3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 3–99
Melbourne Health · Sites in Australia
Ages 18+
Assiut University
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 4
First in 2009; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is above the median of 37 across 281 interventional studies indexed under Anemia, Aplastic.
Median enrollment 36 across the 17 interventional studies. Of the 13 that completed or were terminated, 11 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 8 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
14 studies in Anemia, Aplastic by Novartis: 1 open now, 1 under way, none of them phase 3. Of 12 finished, 7 (58%) have results posted.
Among the 14 studies in Anemia, Aplastic by Novartis, this one is one of 2 that started in 2017, is one of 7 in phase 2, and was the 6th registered.
Novartis’s Anemia, Aplastic studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing eltrombopag in Anemia, Aplastic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 14 in Anemia, Aplastic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy and safety of eltrombopag in combination with cyclosporine alone as first-line therapy on overall hematologic response
This was an interventional phase II, single-arm, multicenter, open-label, study to investigate the efficacy and safety of the combination of eltrombopag and cyclosporine in treatment-naive, adult subjects with severe aplastic anemia (SAA) as first line therapy.
Eligible subjects received eltrombopag and cyclosporine for up to 6 months. Participants who achieved hematologic response any time on or before 6 months were considered as responders; else they were considered as non-responders.
Responders at Month 6 discontinued eltrombopag and started to taper cyclosporine until relapse or Month 24, whichever was early. Responders who relapsed prior to 6 months and non-responders discontinued the treatment at 6 months and were followed-up for 30 days.
Responders who started to taper cyclosporine and relapsed prior to 24 months discontinued cyclosporine and were followed-up for 30 days.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient had SAA characterized by:
At least two of the following (peripheral blood):
Normal defined as the following as determined via the mean of a triplicate ECG
Exclusion Criteria:
Pregnancy statements and requirements:
Pregnancy or nursing (lactating) women Women of , defined as all women physiologically capable of becoming pregnant (or female partners of male patients), unless they were using highly effective methods of contraception during dosing and for 3 months after stopping medication.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received eltrombopag (orally, 150 mg once daily for non-Asian participants / 100 mg once daily for participants of Asian ancestry) in combination with cyclosporine (orally, 10.0 mg/kg/day in divided doses every 12 hours) for up to 6 months. Thereafter, responders at Month 6 were treated with cyclosporine until Month 24
Drug: eltrombopag · Drug: Cyclosporine
Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily for up to 6 months. East and Southeast Asian participants were treated with 100 mg once daily, to adjust for the lower apparent clearance of eltrombopag. All other participants were treated with 150 mg once daily.
Also known as: ETB115
Supplied as oral soft gel capsules. The starting dose was based on body weight at 10.0 mg/kg/day (acceptable rounding range was from 9.5 to 10.5 mg/kg/day) in divided doses every 12 hours. After Day 1, dosing was titrated individually according to therapeutic trough level between 200 and 400 μg/L for 6 months. After 6 months (only for responders at Month 6), tapering of cyclosporine was done as follows: * 6-9 months: at the 6 months visit, the dose was reduced by 25% for 3 months * 9-12 months: at the 9 months visit, the dose was further reduced by 25% for another 3 months * 12-24 months: dose was maintained
Overall Hematologic Response Rate by 6 Months
Overall hematologic response rate by 6 months was defined as the percentage of participants with complete response (CR) or partial response (PR) any time on or before 6 months. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * Absolute neutrophil count (ANC) \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L
Time frame: Up to 6 months
Overall Hematologic Response Rate by 3 Months
Overall hematologic response rate by 3 months was defined as the percentage of participants with CR or PR any time on or before 3 months. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L
Time frame: Up to 3 months
Overall Hematologic Response Rate at 12 and 24 Months
Overall hematologic response rate at 12 and 24 months was defined as the percentage of participants with CR or PR at 12 and 24 months respectively. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC\>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L
Time frame: 12 and 24 months
Duration of First Hematologic Response
Duration of first hematologic response is the time from the date of the start of first response to the date of first relapse. Relapse is defined as no longer meeting definition of PR or CR. Kaplan-Meier method was used for the analysis. If no relapse occurred, the participant was censored at the date of last contact. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24. PR was defined as any 2 of the following parameters at 2 consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL. CR was defined as all 3 parameters meet the following criteria at 2 consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \>1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L
Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Relapse Rate by 6 and 24 Months
Relapse was defined as no longer meeting the definition of PR (and not CR). Relapse rate by 6 months and 24 was defined as the percentage of responders by 6 months who relapsed prior to 6 months or prior to 24 months respectively. Responders by 6 months were participants who achieved CR or PR any time on or before 6 months. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24. PR: any 2 of the following parameters at 2 consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC\>500/μL * Platelet count\>20 000/μL * Reticulocyte count\>60 000/μL. CR: all 3 parameters meet the following criteria at 2 consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC\>1 000/μL * Platelet count\>100 000/μL * Hemoglobin\>10 g/L
Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Percentage of Participants With Evolution to Myelodysplasia, Paroxysmal Nocturnal Hemoglobinuria (PNH) and Leukemia
The percentage of participants with evolution to myelodysplasia, PNH and acute leukemia occurring at any time during the study. Clonal evolution to myelodysplasia was defined as a new marrow cytogenic abnormality with or without characteristic dysplastic marrow findings. Clonal evolution to leukemia was defined as greater than 20% peripheral blood and/or marrow blasts. Clonal evolution to paroxysmal nocturnal hemoglobinuria (PNH) was defined as a clone at baseline \< 10% that rose to greater than 50% on study. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24
Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Percentage of Participants Who Were Red Blood Cells (RBC) Transfusion Independent
Percentage of participants who were RBC transfusion independent at least once by 6 months and by 24 months (responders only). Independence was defined as no RBC transfusion for at least 56 days. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.
Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Percentage of Participants Who Were Platelet Transfusion Independent
Percentage of participants who were platelet transfusion independent at least once by 6 months and by 24 months (responders only). Independence was defined as no platelet transfusion for at least 28 days. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.
Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Longest Duration of Transfusion Independence (Platelet or RBC)
Longest duration of transfusion independence (platelet or RBC) by 6 months and by 24 months (responders only). Transfusion independence was defined as no transfusions required in at least a 28-day period for platelet transfusion and at least 56-day period for RBC transfusion. The duration of the longest interval with transfusion independence was summarized using Kaplan-Meier analysis. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24
Time frame: Up to 6 months (non-responders at Month 6) and up to 24 months (responders at Month 6)
Change From Baseline in Scores of Functional Assessment of Cancer Therapy - General (FACT-G) Patient Reported Outcome
The FACT-G consists of 27-items divided into 4 domains (physical well-being, social well-being, emotional and functional well-being). All items of the FACT-G use a 5 point scale ranging from 0 to 4 with a 0 rating being "not at all" and a 4 rating being "very much". Total FACT-G score is the sum of physical well-being score, social well-being score, emotional well-being score and functional well-being score. Score ranges from 0 to 108, with higher scores indicating better quality of life (QoL). A positive change from baseline indicates improvement in the QoL. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.
Time frame: Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)
Change From Baseline in Scores of FACT - Thrombocytopenia 18 (FACT-TH18) Patient Reported Outcome
The FACT-TH18 is comprised of FACT-G and a thrombocytopenia specific questionnaire. FACT-G consists of 27-items divided into 4 domains (physical, social, emotional and functional well-being). FACT-TH18 has 18 additional items which asks the patient to rate degree of thrombocytopenia. All items of the FACT-TH18 use a 5 point scale ranging from 0 to 4, with 0 = "not at all" and 4 = "very much". Total FACT-TH18 score is the sum of physical, social, emotional and functional well-being scores, and thrombocytopenia subscale. Score ranges from 0 to 180, with higher scores indicating better QoL. A positive change from baseline indicates improvement in the QoL. Results are presented for responders and non-responders. If any participant achieved hematologic response (CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.
Time frame: Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)
Change From Baseline in Scores of Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT- Fatigue) Patient Reported Outcome
The FACIT- Fatigue is a 13-item fatigue subscale that asks the patient to rate their degree of tiredness, weakness and fatigue. All items of the FACIT-Fatigue use a 5-point scale ranging from 0 to 4 with a 0 rating being "not at all" and a 4 rating being "very much". Total score ranges from 0 to 52. Negatively worded items were reverse scored before summing so that higher total scores indicate less fatigue. A positive change from baseline indicates improvement. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.
Time frame: Baseline, every 2 weeks from Week 2 to Week 24 or End of Treatment Period 1 (for all participants); and at Week 38, Week 53, Month 24 or End of Treatment Period 2 (for responders at Month 6 only)
Pharmacokinetic Parameter- Cmax of Eltrombopag When Combined With Cyclosporine
Cmax is the observed maximum plasma concentration following administration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 microgram/milliliter (ug/mL). Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
Time frame: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose.
Pharmacokinetic Parameter-AUClast of Eltrombopag When Combined With Cyclosporine
AUClast is the area under the curve calculated to the last quantifiable concentration point (Tlast). The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
Time frame: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose
Pharmacokinetic Parameter- AUCtau of Eltrombopag When Combined With Cyclosporine
AUCtau is the area under the curve calculated to the end of the dosing interval (tau). The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
Time frame: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose
Pharmacokinetic Parameter- Ctrough of Eltrombopag When Combined With Cyclosporine
Ctrough is the pre-dose plasma concentration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
Time frame: Week 2 at pre-dose
Pharmacokinetic Parameter- Tmax of Eltrombopag When Combined With Cyclosporine
Tmax is the time to reach peak or maximum concentration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
Time frame: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose
Pharmacokinetic Parameter- CLss/F of Eltrombopag When Combined With Cyclosporine
CLss/F is the apparent systemic (or total body) clearance at steady state from plasma. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
Time frame: Week 2 at pre-dose and 2, 4, 6 and 8 hours post-dose
The study was conducted across 20 centers in 9 countries.
| Milestone | Eltrombopag + Cyclosporine |
|---|---|
| Started | 54 |
| East/southeast asian ethnicity | 18 |
| Non-east/southeast asian ethnicity | 36 |
| Completed | 35 |
| Not completed | 19 |
| Withdrew: Adverse event | 6 |
| Withdrew: Death | 5 |
| Withdrew: Technical problems | 4 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Progressive disease | 1 |
| Withdrew: Subject/guardian decision | 1 |
| Milestone | Eltrombopag + Cyclosporine |
|---|---|
| Started | 21 |
| Completed | 11 |
| Not completed | 10 |
| Withdrew: Lack of efficacy | 5 |
| Withdrew: Adverse event | 2 |
| Withdrew: Progressive disease | 2 |
| Withdrew: Physician decision | 1 |
Overall hematologic response rate by 6 months was defined as the percentage of participants with complete response (CR) or partial response (PR) any time on or before 6 months. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * Absolute neutrophil count (ANC) \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L
| Percentage of participants | Eltrombopag + Cyclosporine |
|---|---|
| Overall Hematologic Response Rate by 6 Months | 46.3 (32.6 to 60.4) |
Overall hematologic response rate by 3 months was defined as the percentage of participants with CR or PR any time on or before 3 months. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L
| Percentage of participants | Eltrombopag + Cyclosporine |
|---|---|
| Overall Hematologic Response Rate by 3 Months | 40.7 (27.6 to 55.0) |
Overall hematologic response rate at 12 and 24 months was defined as the percentage of participants with CR or PR at 12 and 24 months respectively. PR was defined as any two of the following parameters at two consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC\>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL CR was defined as all three parameters meet the following criteria at two consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \> 1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L
| Percentage of participants | Eltrombopag + Cyclosporine |
|---|---|
| At 12 months | 18.5 (9.3 to 31.4) |
| At 24 months | 18.5 (9.3 to 31.4) |
Duration of first hematologic response is the time from the date of the start of first response to the date of first relapse. Relapse is defined as no longer meeting definition of PR or CR. Kaplan-Meier method was used for the analysis. If no relapse occurred, the participant was censored at the date of last contact. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24. PR was defined as any 2 of the following parameters at 2 consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC \>500/μL * Platelet count \>20 000/μL * Reticulocyte count \>60 000/μL. CR was defined as all 3 parameters meet the following criteria at 2 consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC \>1 000/μL * Platelet count \>100 000/μL * Hemoglobin \>10 g/L
| Days | Eltrombopag + Cyclosporine |
|---|---|
| Duration of First Hematologic Response | 351.0 (99.0 to NA) |
Relapse was defined as no longer meeting the definition of PR (and not CR). Relapse rate by 6 months and 24 was defined as the percentage of responders by 6 months who relapsed prior to 6 months or prior to 24 months respectively. Responders by 6 months were participants who achieved CR or PR any time on or before 6 months. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24. PR: any 2 of the following parameters at 2 consecutive measurements at least 7 days apart and no platelet transfusion within 7 days of platelet measurement: * ANC\>500/μL * Platelet count\>20 000/μL * Reticulocyte count\>60 000/μL. CR: all 3 parameters meet the following criteria at 2 consecutive measurements at least 7 days apart and no platelet transfusions within 7 days of platelet measurement and no red blood cell transfusion with 14 days of the hemoglobin measurements: * ANC\>1 000/μL * Platelet count\>100 000/μL * Hemoglobin\>10 g/L
| Percentage of participants | Eltrombopag + Cyclosporine |
|---|---|
| By 6 months | 32.0 (14.9 to 53.5) |
| By 24 months | 44.0 (24.4 to 65.1) |
The percentage of participants with evolution to myelodysplasia, PNH and acute leukemia occurring at any time during the study. Clonal evolution to myelodysplasia was defined as a new marrow cytogenic abnormality with or without characteristic dysplastic marrow findings. Clonal evolution to leukemia was defined as greater than 20% peripheral blood and/or marrow blasts. Clonal evolution to paroxysmal nocturnal hemoglobinuria (PNH) was defined as a clone at baseline \< 10% that rose to greater than 50% on study. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24
| Percentage of participants | Eltrombopag + Cyclosporine |
|---|---|
| Percentage of Participants With Evolution to Myelodysplasia, Paroxysmal Nocturnal Hemoglobinuria (PNH) and Leukemia | 0 |
Percentage of participants who were RBC transfusion independent at least once by 6 months and by 24 months (responders only). Independence was defined as no RBC transfusion for at least 56 days. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.
| Participants | Eltrombopag + Cyclosporine |
|---|---|
| Day 1 to 6 months- Responders | 17 |
| Day 1 to 24 months- Responders | 20 |
| Day 1 to 6 months- Non-Responders | 5 |
Percentage of participants who were platelet transfusion independent at least once by 6 months and by 24 months (responders only). Independence was defined as no platelet transfusion for at least 28 days. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.
| Participants | Eltrombopag + Cyclosporine |
|---|---|
| Day 1 to 6 months- Responders | 25 |
| Day 1 to 24 months- Responders | 25 |
| Day 1 to 6 months- Non-responders | 13 |
Longest duration of transfusion independence (platelet or RBC) by 6 months and by 24 months (responders only). Transfusion independence was defined as no transfusions required in at least a 28-day period for platelet transfusion and at least 56-day period for RBC transfusion. The duration of the longest interval with transfusion independence was summarized using Kaplan-Meier analysis. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24
| Days | Eltrombopag + Cyclosporine |
|---|---|
| Day 1 to 6 months- Responders | NA (NA to NA) |
| Day 1 to 24 months- Responders | NA (498.0 to NA) |
| Day 1 to 6 months- Non-Responders | 87.0 (48.0 to NA) |
The FACT-G consists of 27-items divided into 4 domains (physical well-being, social well-being, emotional and functional well-being). All items of the FACT-G use a 5 point scale ranging from 0 to 4 with a 0 rating being "not at all" and a 4 rating being "very much". Total FACT-G score is the sum of physical well-being score, social well-being score, emotional well-being score and functional well-being score. Score ranges from 0 to 108, with higher scores indicating better quality of life (QoL). A positive change from baseline indicates improvement in the QoL. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.
| Score on a scale | Eltrombopag + Cyclosporine |
|---|---|
| Week 2 (Treatment period 1) - Responders | -2.0 (-26 to 30) |
| Week 4 (Treatment period 1) - Responders | -3.0 (-22 to 23) |
| Week 6 (Treatment period 1) - Responders | -0.3 (-48 to 30) |
| Week 8 (Treatment period 1) - Responders | 0.0 (-25 to 30) |
| Week 10 (Treatment period 1) - Responders | -1.3 (-43 to 33) |
| Week 12 (Treatment period 1) - Responders | 0.8 (-40 to 30) |
| Week 14 (Treatment period 1) - Responders | 1.0 (-44 to 29) |
| Week 16 (Treatment period 1) - Responders | -2.0 (-51 to 35) |
| Week 18 (Treatment period 1) - Responders | 3.0 (-41 to 37) |
| Week 20 (Treatment period 1) - Responders | -1.0 (-46 to 41) |
| Week 22 (Treatment period 1) - Responders | 1.0 (-43 to 39) |
| Week 24 (Treatment period 1) - Responders | 1.8 (-46 to 35) |
| Week 26 (Treatment period 1) - Responders | 1.0 (-51 to 38) |
| End of treatment period 1 - Responders | -1.0 (-51 to 38) |
| Week 38 (Treatment period 2)- Responders | 5.7 (-43 to 47) |
| Week 53 (Treatment period 2)- Responders | 4.0 (-46 to 42) |
| Month 24 (Treatment period 2)- Responders | 22.0 (-50 to 84) |
| End of treatment period 2 - Responders | 13.5 (-5 to 47) |
| Week 2 (Treatment period 1) - Non-Responders | -0.3 (-34 to 21) |
| Week 4 (Treatment period 1) - Non-Responders | -1.0 (-42 to 22) |
| Week 6 (Treatment period 1) - Non-Responders | -3.6 (-45 to 17) |
| Week 8 (Treatment period 1) - Non-Responders | 1.5 (-36 to 99) |
| Week 10 (Treatment period 1) - Non-Responders | -0.9 (-27 to 25) |
| Week 12 (Treatment period 1) - Non-Responders | -0.3 (-54 to 26) |
| Week 14 (Treatment period 1) - Non-Responders | -0.3 (-39 to 28) |
| Week 16 (Treatment period 1) - Non-Responders | 0.3 (-50 to 23) |
| Week 18 (Treatment period 1) - Non-Responders | -2.6 (-45 to 19) |
| Week 20 (Treatment period 1) - Non-Responders | -1.5 (-44 to 22) |
| Week 22 (Treatment period 1) - Non-Responders | -1.0 (-45 to 12) |
| Week 24 (Treatment period 1) - Non-Responders | 2.7 (-30 to 18) |
| Week 26 (Treatment period 1) - Non-Responders | -2.7 (-25 to 24) |
| End of treatment period 1 - Non-Responders | -2.0 (-30 to 24) |
The FACT-TH18 is comprised of FACT-G and a thrombocytopenia specific questionnaire. FACT-G consists of 27-items divided into 4 domains (physical, social, emotional and functional well-being). FACT-TH18 has 18 additional items which asks the patient to rate degree of thrombocytopenia. All items of the FACT-TH18 use a 5 point scale ranging from 0 to 4, with 0 = "not at all" and 4 = "very much". Total FACT-TH18 score is the sum of physical, social, emotional and functional well-being scores, and thrombocytopenia subscale. Score ranges from 0 to 180, with higher scores indicating better QoL. A positive change from baseline indicates improvement in the QoL. Results are presented for responders and non-responders. If any participant achieved hematologic response (CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.
| Score on a scale | Eltrombopag + Cyclosporine |
|---|---|
| Week 2 (Treatment period 1) - Responders | 2.3 (-43 to 43) |
| Week 4 (Treatment period 1) - Responders | -1.5 (-37 to 54) |
| Week 6 (Treatment period 1) - Responders | 8.4 (-62 to 70) |
| Week 8 (Treatment period 1) - Responders | 9.0 (-34 to 66) |
| Week 10 (Treatment period 1) - Responders | 3.4 (-44 to 73) |
| Week 12 (Treatment period 1) - Responders | 9.3 (-45 to 69) |
| Week 14 (Treatment period 1) - Responders | 6.4 (-45 to 63) |
| Week 16 (Treatment period 1) - Responders | 7.8 (-47 to 68) |
| Week 18 (Treatment period 1) - Responders | 13.9 (-46 to 77) |
| Week 20 (Treatment period 1) - Responders | 11.8 (-48 to 81) |
| Week 22 (Treatment period 1) - Responders | 13.5 (-46 to 81) |
| Week 24 (Treatment period 1) - Responders | 14.5 (-48 to 72) |
| Week 26 (Treatment period 1) - Responders | 18.2 (-57 to 72) |
| End of treatment period 1 - Responders | 13.9 (-57 to 72) |
| Week 38 (Treatment period 2)- Responders | 21.7 (-50 to 88) |
| Week 53 (Treatment period 2)- Responders | 22.0 (-50 to 84) |
| Month 24 (Treatment period 2)- Responders | 35.7 (5 to 95) |
| End of treatment period 2 - Responders | 6.9 (-55 to 35) |
| Week 2 (Treatment period 1) - Non-Responders | 0.6 (-78 to 39) |
| Week 4 (Treatment period 1) - Non-Responders | 2.1 (-77 to 45) |
| Week 6 (Treatment period 1) - Non-Responders | -1.5 (-97 to 42) |
| Week 8 (Treatment period 1) - Non-Responders | 2.0 (-54 to 43) |
| Week 10 (Treatment period 1) - Non-Responders | 5.2 (-22 to 41) |
| Week 12 (Treatment period 1) - Non-Responders | 1.8 (-101 to 49) |
| Week 14 (Treatment period 1) - Non-Responders | 2.8 (-64 to 41) |
| Week 16 (Treatment period 1) - Non-Responders | 2.1 (-98 to 38) |
| Week 18 (Treatment period 1) - Non-Responders | 0.5 (-78 to 27) |
| Week 20 (Treatment period 1) - Non-Responders | 2.4 (-68 to 43) |
| Week 22 (Treatment period 1) - Non-Responders | -1.3 (-67 to 39) |
| Week 24 (Treatment period 1) - Non-Responders | 0.7 (-31 to 43) |
| Week 26 (Treatment period 1) - Non-Responders | -1.4 (-24 to 41) |
| End of treatment period 1 - Non-Responders | -1.4 (-27 to 41) |
The FACIT- Fatigue is a 13-item fatigue subscale that asks the patient to rate their degree of tiredness, weakness and fatigue. All items of the FACIT-Fatigue use a 5-point scale ranging from 0 to 4 with a 0 rating being "not at all" and a 4 rating being "very much". Total score ranges from 0 to 52. Negatively worded items were reverse scored before summing so that higher total scores indicate less fatigue. A positive change from baseline indicates improvement. Results are presented for responders and non-responders. If any participant achieved hematologic response (either CR or PR) any time on or before 6 months, they were considered as responders, else they were considered as non-responders. Only participants who achieved hematologic response of CR or PR at Month 6 were followed up until Month 24.
| Score on a scale | Eltrombopag + Cyclosporine |
|---|---|
| Week 2 (Treatment period 1) - Responders | 3.0 (-13 to 34) |
| Week 4 (Treatment period 1) - Responders | 2.0 (-16 to 22) |
| Week 6 (Treatment period 1) - Responders | 4.0 (-22 to 32) |
| Week 8 (Treatment period 1) - Responders | 6.0 (-7 to 29) |
| Week 10 (Treatment period 1) - Responders | 4.5 (-11 to 30) |
| Week 12 (Treatment period 1) - Responders | 5.5 (-11 to 31) |
| Week 14 (Treatment period 1) - Responders | 6.5 (-5 to 26) |
| Week 16 (Treatment period 1) - Responders | 6.0 (-5 to 28) |
| Week 18 (Treatment period 1) - Responders | 7.0 (-5 to 28) |
| Week 20 (Treatment period 1) - Responders | 6.0 (-5 to 29) |
| Week 22 (Treatment period 1) - Responders | 6.0 (-8 to 33) |
| Week 24 (Treatment period 1) - Responders | 6.0 (-5 to 29) |
| Week 26 (Treatment period 1) - Responders | 7.0 (-9 to 32) |
| End of treatment period 1 - Responders | 6.0 (-9 to 32) |
| Week 38 (Treatment period 2)- Responders | 6.0 (-8 to 33) |
| Week 53 (Treatment period 2)- Responders | 8.0 (-2 to 41) |
| Month 24 (Treatment period 2)- Responders | 9.0 (1 to 31) |
| End of treatment period 2 - Responders | 11.5 (-5 to 42) |
| Week 2 (Treatment period 1) - Non-Responders | -0.5 (-23 to 19) |
| Week 4 (Treatment period 1) - Non-Responders | -2.0 (-38 to 20) |
| Week 6 (Treatment period 1) - Non-Responders | 0.0 (-43 to 18) |
| Week 8 (Treatment period 1) - Non-Responders | -1.0 (-27 to 14) |
| Week 10 (Treatment period 1) - Non-Responders | 0.5 (-25 to 16) |
| Week 12 (Treatment period 1) - Non-Responders | -1.0 (-42 to 15) |
| Week 14 (Treatment period 1) - Non-Responders | -1.5 (-43 to 16) |
| Week 16 (Treatment period 1) - Non-Responders | -0.5 (-46 to 15) |
| Week 18 (Treatment period 1) - Non-Responders | -6.0 (-43 to 15) |
| Week 20 (Treatment period 1) - Non-Responders | -6.0 (-45 to 22) |
| Week 22 (Treatment period 1) - Non-Responders | -4.0 (-45 to 15) |
| Week 24 (Treatment period 1) - Non-Responders | -7.0 (-19 to 12) |
| Week 26 (Treatment period 1) - Non-Responders | -8.0 (-19 to 15) |
| End of treatment period 1 - Non-Responders | -4.0 (-19 to 15) |
Cmax is the observed maximum plasma concentration following administration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 microgram/milliliter (ug/mL). Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
| microgram/milliliter (ug/mL) | Eltrombopag + Cyclosporine |
|---|---|
| East/Southeast Asian ethnicity | 29.1 ± 43.5 |
| Non-East/Southeast Asian ethnicity | 38.7 ± 38.0 |
AUClast is the area under the curve calculated to the last quantifiable concentration point (Tlast). The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
| hour*microgram/milliliter (h*ug/mL) | Eltrombopag + Cyclosporine |
|---|---|
| East/Southeast Asian ethnicity | 583 ± 38.3 |
| Non-East/Southeast Asian ethnicity | 702 ± 59.9 |
AUCtau is the area under the curve calculated to the end of the dosing interval (tau). The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
| hour*microgram/milliliter (h*ug/mL) | Eltrombopag + Cyclosporine |
|---|---|
| East/Southeast Asian ethnicity | 686 ± 32.4 |
| Non-East/Southeast Asian ethnicity | 727 ± 33.0 |
Ctrough is the pre-dose plasma concentration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
| microgram/milliliter (ug/mL) | Eltrombopag + Cyclosporine |
|---|---|
| East/Southeast Asian ethnicity | 19.3 ± 45.3 |
| Non-East/Southeast Asian ethnicity | 27.2 ± 44.1 |
Tmax is the time to reach peak or maximum concentration. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
| Hours | Eltrombopag + Cyclosporine |
|---|---|
| East/Southeast Asian ethnicity | 5.79 (1.93 to 8.00) |
| Non-East/Southeast Asian ethnicity | 3.75 (0.00 to 8.00) |
CLss/F is the apparent systemic (or total body) clearance at steady state from plasma. The plasma samples from all participants were assayed for eltrombopag concentrations using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS). The lower limit of quantitation (LLOQ) was 0.1 ug/mL. Concentration values below the LLOQ were reported as zero, and missing samples were labeled accordingly. Results are reported by ethnicity: East/Southeast Asian participants received eltrombopag planned dose of 100mg/day and all other participants received eltrombopag planned dose of 150mg/day.
| milliliter/hour (mL/h) | Eltrombopag + Cyclosporine |
|---|---|
| East/Southeast Asian ethnicity | 146 ± 32.4 |
| Non-East/Southeast Asian ethnicity | 206 ± 33.0 |
Collected over From day of first dose of study medication to 30 days after last dose of study medication, assessed up to 25 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Eltrombopag + Cyclosporine | 8/54 (14.8%) | 27/54 (50%) | 47/54 (87%) |
| Event | Eltrombopag + Cyclosporine |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 10/54 |
| PyrexiaGeneral disorders | 2/54 |
| Drug-induced liver injuryHepatobiliary disorders | 2/54 |
| COVID-19Infections and infestations | 2/54 |
| Septic shockInfections and infestations | 2/54 |
| HyperkalaemiaMetabolism and nutrition disorders | 2/54 |
| Cardiac arrestCardiac disorders | 1/54 |
| Dental cariesGastrointestinal disorders | 1/54 |
| Gastric dysplasiaGastrointestinal disorders | 1/54 |
| HaematocheziaGastrointestinal disorders | 1/54 |
| Event | Eltrombopag + Cyclosporine |
|---|---|
| Blood bilirubin increasedInvestigations | 22/54 |
| NauseaGastrointestinal disorders | 16/54 |
| DiarrhoeaGastrointestinal disorders | 12/54 |
| Alanine aminotransferase increasedInvestigations | 12/54 |
| VomitingGastrointestinal disorders | 11/54 |
| Aspartate aminotransferase increasedInvestigations | 10/54 |
| Blood creatinine increasedInvestigations | 10/54 |
| HypomagnesaemiaMetabolism and nutrition disorders | 10/54 |
| HeadacheNervous system disorders | 10/54 |
| Oedema peripheralGeneral disorders | 8/54 |
| Age, Continuous(Years) | Eltrombopag + Cyclosporine |
|---|---|
| Mean | 52.0 ± 17.88 |
| Sex: Female, Male(Participants) | Eltrombopag + Cyclosporine |
|---|---|
| Female | 20 |
| Male | 34 |
| Race/Ethnicity, Customized(Participants) | Eltrombopag + Cyclosporine |
|---|---|
| Hispanic or Latino | 22 |
| Southeast Asian | 11 |
| East Asian | 7 |
| West Asian | 5 |
| Other | 4 |
| South Asian | 3 |
| Mixed ethnicity | 1 |
| Not reported | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from May 2017 to primary completion in Nov 2020, 41 months.
Results were first posted in Dec 2023, 3 years 1 month after primary completion.
Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 41 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Eltrombopag · Cyclosporine